AYTU$2.13
$2.17
Chart
Performance
Key Stats
AI AYTU Summary
Powered by LiveAIAI Scoreboard
Powered by LiveAIOverall Analysis
BuyAytu BioPharma shows strong potential driven by its focus on the growing CNS market, particularly with EXXUA. While recent financial performance indicates challenges, the strategic positioning and analyst optimism suggest a positive outlook. Investors should monitor upcoming EXXUA launch and revenue growth.
Thematic
Aytu BioPharma is well-positioned within the expanding pharmaceutical market, with a strategic focus on CNS disorders like ADHD and Major Depressive Disorder (MDD). The upcoming launch of EXXUA™ (gepirone) for MDD is a significant thematic driver, targeting a substantial market with unmet needs.
Fundamental
Aytu BioPharma has shown significant revenue growth in recent quarters, driven by its ADHD and pediatric portfolios. However, profitability remains a challenge, with net losses reported in some periods. The company's balance sheet shows increasing cash reserves and managed debt levels.
Technical
Aytu BioPharma's stock shows a positive short-term trend with significant gains over the past month and week. While momentum indicators suggest a potentially overbought condition, moving averages confirm an overall bullish trend.
| Factor | Score |
|---|---|
| Central Nervous System (CNS) Market Growth | 85 |
| EXXUA™ Launch and Commercialization | 88 |
| Regulatory Approvals and Pipeline | 90 |
| Financial Restructuring and Capital Access | 75 |
| Competitive Landscape | 60 |
| Factor | Score |
|---|---|
| Revenue Growth | 80 |
| Profitability | 70 |
| Balance Sheet Health | 75 |
| Debt Management | 70 |
| Valuation Metrics | 65 |
| Factor | Score |
|---|---|
| Short-Term Price Trend | 85 |
| Momentum Indicators | 60 |
| Moving Averages | 75 |
| Analyst Price Targets | 80 |
| Volatility | 50 |
AI Investing Checklist
Powered by LiveAICalendar
December 2020
9
Next Dividend Date
May 2025
15
Next Earnings Date
H: $-0.02
A: $-0.02
L: $-0.02
H: 19.61M
A: 18.83M
L: 18.06M
Profile
Aytu BioPharma, Inc., a pharmaceutical company, focuses on commercializing novel therapeutics in the United States and internationally. The company offers prescription products for the treatment of attention deficit hyperactivity disorder (ADHD), including Adzenys XR-ODT extended-release orally disintegrating tablets for patients from six years of age and above, and Cotempla XR-ODT extended-release orally disintegrating tablets for patients from six to seventeen years old. It also provides pediatric prescription product portfolio comprising Karbinal ER, an extended-release carbinoxamine (antihistamine) suspension indicated to treat numerous allergic conditions for patients two years and above; and Poly-Vi-Flor and Tri-Vi-Flor complementary prescription fluoride-based multi-vitamin products containing combinations of fluoride and vitamins in liquid and chewable tablet form for infants and children with fluoride deficiency. The company was formerly known as Aytu BioScience, Inc. and changed its name to Aytu BioPharma, Inc. in March 2021. Aytu BioPharma, Inc. is headquartered in Denver, Colorado.
Seasonals
Price Target
10.50 USD
The 39 analysts offering 1 year price forecasts for AYTU have a max estimate of 12.00 and a min estimate of 9.00.
Debt Level and Coverage
Financial Position Analysis
Ownership
Capital Structure
Valuation - Summary
Valuation - Ratios
Revenue to Profit Conversion
Balance Sheet
Income Statement
Cash Flow
Related Companies
Powered by LiveAIWeight: 95
Specialty pharmaceutical company focused on commercializing products for rare neuromuscular and neurological diseases, aligning with AYTU's rare disease focus and commercialization model.
Weight: 93
Specialty pharmaceutical company focused on developing and commercializing therapies for rare neurological diseases, directly comparable to AYTU's niche therapeutic and commercial strategy.
Weight: 92
Develops and commercializes novel therapies for rare kidney and metabolic diseases, demonstrating a strong thematic overlap with AYTU's rare disease and specialty commercialization efforts.
Weight: 90
Specialty pharmaceutical company focused on kidney and cardiorenal diseases, employing a similar commercialization strategy for focused therapeutic areas.